Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director James George Robinson acquired 8,500 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was acquired at an average cost of $1.76 per share, with a total value of $14,960.00. Following the acquisition, the director now owns 3,335,150 shares of the company’s stock, valued at $5,869,864. The purchase was disclosed in a document filed with the SEC, which is available through this link.

James George Robinson also recently made the following trade(s):

  • On Tuesday, May 28th, James George Robinson acquired 9,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.68 per share, with a total value of $15,120.00.
  • On Friday, May 24th, James George Robinson acquired 8,000 shares of Nymox Pharmaceutical stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $12,720.00.

Nymox Pharmaceutical stock opened at $1.59 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.04 and a quick ratio of 8.01. Nymox Pharmaceutical Corp has a 12 month low of $1.25 and a 12 month high of $3.90.

Nymox Pharmaceutical (NASDAQ:NYMX) last released its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The business had revenue of $0.03 million during the quarter. Nymox Pharmaceutical had a negative return on equity of 175.82% and a negative net margin of 6,101.69%.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Nymox Pharmaceutical by 0.4% in the first quarter. BlackRock Inc. now owns 1,641,663 shares of the biopharmaceutical company’s stock worth $3,234,000 after purchasing an additional 7,336 shares during the period. Northern Trust Corp boosted its holdings in shares of Nymox Pharmaceutical by 2.2% during the fourth quarter. Northern Trust Corp now owns 277,557 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 6,026 shares during the period. Bank of America Corp DE boosted its holdings in shares of Nymox Pharmaceutical by 130.1% during the fourth quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 83,925 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Nymox Pharmaceutical by 10.8% during the fourth quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 13,103 shares during the period. Finally, State of Wisconsin Investment Board boosted its holdings in shares of Nymox Pharmaceutical by 29.7% during the first quarter. State of Wisconsin Investment Board now owns 44,600 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 10,200 shares during the period. 5.66% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/james-george-robinson-purchases-8500-shares-of-nymox-pharmaceutical-corp-nymx-stock/3030079.html.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Further Reading: Diversification For Individual Investors

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.